Anwaar Saeed, MD
Associate Professor of Medicine & Chief of GI Medical Oncology
Biography:
Anwaar Saeed, MD, is an Associate Professor of Medicine and the Chief of Gastrointestinal Medical Oncology at the University of Pittsburgh Medical Center (UPMC) and UPMC Hillman Cancer Center. Dr. Saeed’s clinical research is focused on developmental therapeutics and immune modulatory approaches in gastrointestinal malignancies, specifically gastric, esophageal, hepatocellular and colorectal cancer as well as immunoprevention in the high-risk gastrointestinal cancer populations. She is a prolific clinical researcher and multiple award winner. She has published more than 250 peer reviewed papers, posters and book chapters, and have led more than 40 clinical trials, including several investigator-initiated trials focused on various immune modulatory regimens. She serves at the NCI Gastrointestinal Steering Committee Esophagogastric Task Force (EG TF). She also serves as the Vice Chair of the NSABP Foundation Colorectal Cancer Committee. Recently, Dr Saeed was named Hillman Senior Fellow for Innovative Cancer Research.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, Arcus therapeutics, KAHR medical, and Daiichi SankyoTopic:therapeutic applications in GI malignanciesDate added:08/26/2024Date updated:08/26/2024
-
Attribution:OtherType of financial relationship:Contracted ResearchIneligible company:AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medicalTopic:Therapeutic applications in GI malignanciesDate added:08/26/2024Date updated:08/26/2024